Hormone replacement therapy is associated with reduced hepatocellular carcinoma risk and improved survival in postmenopausal women with hepatitis B: A nationwide long-term population-based cohort study

Chun-Hsiang Wang¹,², Ruey-Chang Lin¹*, Hua-Yin Hsu³*, Yuan-Tsung Tseng⁴*

¹ Department of Hepatogastroenterology, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan, Taiwan, ² Department of Optometry, Chung Hwa Medical University, Tainan, Taiwan, ³ Departments of Nursing, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan City, Taiwan, ⁴ Committee of Medical Research, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan, Taiwan

* These authors contributed equally to this work.

*b891040733@yahoo.com.tw

Abstract

Postmenopausal women with hepatitis B virus (HBV) infection are more likely to have accelerated liver fibrosis, eventually advancing to liver cirrhosis or hepatocellular carcinoma (HCC). The association between sex hormones and HBV-related HCC risk is unclear. We investigated whether hormone replacement therapy (HRT) is beneficial to postmenopausal women with HBV infection. This retrospective study selected the data of 44,465 patients with HBV infection between January 2000 and December 2018 from Taiwan’s National Health Insurance Research Database. After excluding patients with preexisting liver diseases, liver cirrhosis, or liver malignancies, we grouped the remaining 10,474 patients by whether they had undergone HRT for at least 3 months (n = 5,638) and whether they had not received HRT (n = 4,836). After propensity score matching, we assigned 3080 patients to an HRT cohort and matched them (1:1) with those in a non-HRT cohort. The incidence of HCC (P < 0.022) and all-cause mortality rate (P < 0.001) were lower in the HRT cohort than in the non-HRT cohort. The liver cirrhosis risk was not significantly higher in the HRT cohort (P = 0.355). HRT is associated with reduced HCC risk and improved survival outcomes but is unrelated to liver cirrhosis development in postmenopausal women.

Introduction

Although the prevalence of hepatocellular carcinoma (HCC) varies worldwide, a sex disparity can be observed in its causes [1] and incidence [2, 3]. The male-to-female ratio of patients with a grave prognosis of HCC is 3:1, and such HCC cases are commonly linked to certain types of chronic viral hepatitis, particularly hepatitis B virus (HBV) [4, 5]. The incidence of HBV-associated HCC tends to be higher in men and postmenopausal women than in other women [6–
Because patients with HCC are predominantly men, sex hormones may influence the development of HCC and its prognosis. The protective effect of sex hormones against HCC development has been addressed by many experts [9, 10]. Hassan et al. conducted a case–control study and demonstrated that estrogen use was associated with a reduced risk of HCC and increased overall survival times in patients with HCC [10]. Evidence regarding the benefits of sex hormone use in menopausal women with HBV infection is contradictory. In addition, few detailed observational studies with large sample sizes have been conducted on this question. Accordingly, we conducted the present large-scale long-term population-based study to identify the effects of hormone replacement therapy (HRT) on the development of liver cirrhosis and HCC and on all-cause mortality in postmenopausal women with chronic HBV infection.

Materials and methods

Data source

Using the Taiwan National Health Insurance Research Database (NHIRD), we organized and performed a nested case–control cohort study. Taiwan’s National Health Insurance (NHI) is a universal health insurance program that is compulsory by law, has operated since 1995, and provides comprehensive medical coverage to the 23 million residents of Taiwan. The NHIRD is a database of insurance claims for services performed within the NHI system.

Patient information in the database includes medical history, personal data, medications, surgical intervention history, and patient conditions identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. The NHIRD protects personal electronic data with strict confidentiality guidelines. The data used in the study are available from the NHIRD for researchers who meet the criteria for access to confidential data, but they cannot be shared publicly because of legal restrictions imposed by the government of Taiwan in relation to the "Personal Information Protection Act." Requests for data can be sent as a formal proposal to the NHIRD (https://dep.mohw.gov.tw/dos/np-2497-113.html). The study protocol was approved by the Research Ethics Committee of Show Chwan Memorial Hospital (IRB-No: 1080703), and the informed consent requirement was waived because the datasets in the NHIRD have no identifiable personal information.

Identification of patients

We organized claims from 2 million Taiwan residents with longitudinal follow-up from January 1, 2000, to December 31, 2018. Women aged 35 years or over were enrolled because the onset of HCC among women usually occurs after the age of 35 years.

Inclusion and exclusion criteria

Patients who were older than 35 years and had a diagnosis of HBV (ICD-9-CM codes: 070.2x, 070.3x, and V02.61; ICD-10-CM code: B18.1) were eligible for inclusion in the study. We excluded patients with alcoholic liver disease (ICD-9-CM codes: 291, 303.0, 303.9, 305.0, 571.0, 571.2, and 571.3; ICD-10-CM code: K70.x), any history of malignancy (ICD-9-CM codes: 140–208, 230–231, and 233–234; ICD-10-CM codes: C00–C95, D00–D02, D05–D09), HCC (ICD-9-CM code: 155.0; ICD-10-CM code: C22.0), human immunodeficiency virus coinfection (ICD-9-CM codes: 042, 044, and V08; ICD-10-CM code: B20), liver cirrhosis (ICD-9-CM code: 571.5; ICD-10-CM code: K74.6), acute or subacute necrosis of the liver (ICD-9-CM code: 570; ICD-10-CM code: K72.0), esophageal varices (ICD-9-CM code: 456.2; ICD-10-CM code: I85.01), ascites (ICD-9-CM code: 789.5; ICD-10-CM code: R18), hepatic encephalopathy
Hormone exposure

The prescriptions for HRT were estrogens (conjugated estrogen and estradiol), progestins (progesterone, norethindrone, cyproterone, ethisterone, medroxyprogesterone, and norgestrel), and ovulation stimulators (clomiphene). We calculated the total dispensed days for each HRT prescription during the follow-up period as an indicator of the duration of hormone exposure. The patients were assigned to an HRT cohort or a non-HRT cohort. Specifically, patients with HBV who were prescribed HRT for \( \geq 90 \) days were assigned to the HRT cohort. Patients with HBV who had never used hormones were assigned to the non-HRT cohort. The index date for each hormone user was defined as the date of their first hormone prescription. All hormone nonusers were assigned the same date as an index date. Patients who had a hormone prescription before being diagnosed with chronic HBV infection were excluded from the study. To examine the dose–effect relationship, we divided the HRT cohort into three subgroups on the basis of hormone use duration (<12, 12–36, and >36 months).

Propensity score matching

We used a propensity score matching (PSM) design to sufficiently reduce confounding variables between the HRT and non-HRT cohorts. A logistic regression model was used for propensity score calculation; the covariates used in the model were age, hypertensive cardiovascular disease (HCD), hyperlipidemia, diabetes mellitus (DM), chronic kidney disease (CKD), Charlson comorbidity index (CCI), and medication use (aspirin, statins, angiotensin-converting enzyme inhibitors (ACEi), \( \beta \)-blockers, and antiviral treatments). The calculated propensity score was then used to identify a unique patient in the non-HRT cohort whose score was closest to that of each patient in the HRT cohort (1:1 matching). A flowchart of HBV patient recognition and matching is presented in Fig 1.

Potential confounders

To adjust for comorbidities, we searched the NHIRD for age, HCD, hyperlipidemia, DM, CKD, and CCI. The baseline characteristics (age, comorbidities, and medication history) and treatment protocol of the cohorts were recorded. The CCI is a system for the classification of disease severity by using a claims-based algorithm to estimate weighted morbidity. We also searched for diseases and medications that might affect the outcomes (i.e., liver cirrhosis, HCC, and mortality). Medications considered included antiviral medications (pegylated-interferon-alfa-2a, entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, lamivudine, adefovir, and telbivudine), aspirin, statins, ACEi, and \( \beta \)-blockers.
HRT is associated with reduced HCC risk in postmenopausal women with HBV

Patients with HBV
N=44465

5352 Patients excluded: HRT less than 3 months

HRT(3m)
N=6835

Non- HRT
N=32278

28639 Patients excluded before index date:
1. liver cirrhosis
2. hepatocellular carcinoma
3. acute and subacute necrosis of liveresophageal varices
4. ascites
5. hepatic encephalopathy
6. hepatopulmonary hypertensionhepatorenal syndrome
7. spontaneous bacterial peritonitis
8. coagulation disorders
9. hepatitis A,C,D,E
10. autoimmune hepatitis
11. male
12. Age less than 35

HRT(3m)
N=5638

Non- HRT
N=4836

Matching 1:1
HCD, Hyperlipidemia, DM,
CKD, CCI
Medication use: aspirin, statins, ACEi, β-blocker,
Antiviral treatment

HRT(3m)
N=3080

Non- HRT
N=3080
Study outcomes

The primary outcomes considered were the development of HCC, the development of liver cirrhosis, and death. To avoid potential immortal time bias, outcomes were assessed after a 90-day period of hormone exposure. All patients were followed up from the index date until the date of diagnosis of HCC or cirrhosis, the date of death (obtained from the NHIRD), or the end of 2018. We used 90 days as the washout period to minimize the influence of other factors in patients with newly diagnosed outcomes at the endpoint.

Statistical analysis

We conducted between-group comparisons by using the paired t-test for continuous variables and McNemar’s test for categorical variables. Cox regression analysis with covariates was used to estimate the relationship and the risk of cirrhosis, all-cause mortality, and HCC development between the HRT and non-HRT cohorts. We performed the same analysis in the subgroups with different comorbidities of chronic HBV infection (e.g., DM, HCD, and hyperlipidemia). The hazard ratios (HRs) and 95% confidence intervals (CIs) for the outcomes were measured for the HRT cohort and compared with those derived for the non-HRT cohort after adjustment for covariables. The Kaplan–Meier method was used to estimate the outcomes of the different study cohorts. The differences between the curves were examined through a log-rank test. Baseline characteristics were matched by PSM to reduce potential selection bias. PSM was performed using multivariate logistic regression analysis and nearest neighbor matching with the R package “MatchIt” (version 3.4.2). The cumulative probability of competing risks was adjusted using the R package “cmprsk” (version 3.4.2). All data management procedures were performed using SPSS 21.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was set at P < 0.05.

Results

We identified a total of 44,465 patients with chronic HBV infection. After applying the exclusion criteria and PSM, we included 6160 patients divided evenly between the HRT cohort, which comprised patients who received HRT for ≥ 90 days (n = 3080) and the non-HRT cohort, which comprised patients who did not receive HRT (n = 3080). The demographic characteristics of the two cohorts after matching are presented in Table 1. The mean follow-up periods from the index date were 15.1 ± 4.1 and 15.0 ± 4.1 years for the HRT and non-HRT cohorts, respectively (P = 0.310).

The CCI scores were fully matched between the HRT and non-HRT cohorts (HRT vs. non-HRT, mean: 5.1±2.2; P = 1.000). Compared with the non-HRT cohort, the HRT cohort showed a significantly lower prevalence of HCC (0.6% vs. 1.2%; P = 0.022) and rate of all-cause mortality (2.3% vs. 4.6%; P < 0.001) but not liver cirrhosis (2.6% vs. 3.0%; P = 0.355) (Table 2). With regard to HCC occurrence, the 18-year cumulative incidences was significantly lower in HRT as compared with non-HRT cohort (P = 0.014) (Fig 2). The chance of survival was significantly higher in the HRT than in the non-HRT cohort (P < 0.001) (Fig 3).

Furthermore, multivariate analysis revealed that the HRT cohort had a significantly lower risk of HCC (adjusted HR, 0.50; 95% CI, 0.29–0.87) and all-cause mortality (adjusted HR, 0.49; 95% CI, 0.37–0.65) but not liver cirrhosis (adjusted HR, 0.82; 95% CI, 0.60–1.10) (Table 3).
We stratified the participants into three groups based on exposure duration to determine the associations between HRT and the risks of liver cirrhosis, HCC, and all-cause mortality. For the liver cirrhosis, HCC, and all-cause mortality risks, the adjusted HRs (95% CIs) for

Table 1. Characteristics of patients in the Hormone Replacement Therapy (HRT) Cohort and the non-HRT cohort after matching.

| Variable          | HRT         | %  | Non-HRT | %  | P   |
|------------------|-------------|----|---------|----|-----|
| No. of patients  | 3080        | 3080|
| Age              | 55.4±12.0   |    | 55.4±12.0| 1.000|
| 35–50            | 1097        | 35.6%| 1097| 35.6%| 1.000|
| 51–65            | 1301        | 42.2%| 1301| 42.2%| 1.000|
| >65              | 682         | 22.1%| 682| 22.1%| 1.000|
| HCD              | NO          | 2221| 72.1%| 2221| 72.1%| 1.000|
|                 | YES         | 859 | 27.9%| 859 | 27.9%|
| Hyperlipidemia   | NO          | 1942| 63.1%| 1942| 63.1%| 1.000|
|                 | YES         | 1138| 36.9%| 1138| 36.9%|
| DM               | NO          | 2574| 83.6%| 2574| 83.6%| 1.000|
|                 | YES         | 506 | 16.4%| 506 | 16.4%|
| CKD              | NO          | 3012| 97.8%| 3012| 97.8%| 1.000|
|                 | YES         | 68  | 2.2% | 68  | 2.2% |
| CCI              |             | 5.1±2.2| 5.1±2.2| 1.000|
| Medications      |             |    |       |    |     |  
| Aspirin          | NO          | 2280| 74.0%| 2280| 74.0%| 1.000|
|                 | YES         | 800 | 26.0%| 800 | 26.0%|
| Statins          | NO          | 2396| 77.8%| 2396| 77.8%| 1.000|
|                 | YES         | 684 | 22.2%| 684 | 22.2%|
| ACEi             | NO          | 2503| 81.3%| 2503| 81.3%| 1.000|
|                 | YES         | 577 | 18.7%| 577 | 18.7%|
| β-blockers       | NO          | 1516| 49.2%| 1516| 49.2%| 1.000|
|                 | YES         | 1564| 50.8%| 1564| 50.8%|
| Antiviral treatment | NO       | 2730| 88.6%| 2730| 88.6%| 1.000|
|                 | YES         | 350 | 11.4%| 350 | 11.4%|

^aHCD, hypertensive cardiovascular disease.  
bDM, diabetes mellitus.  
cCKD, chronic kidney disease.  
dCCI, Charlson comorbidity index.  
eACEi, angiotensin converting enzyme inhibitors.

https://doi.org/10.1371/journal.pone.0271790.t001

Table 2. Outcomes of patients in the Hormone Replacement Therapy (HRT) and non-HRT cohorts.

| Variable          | HRT* N = 3080 | %  | Non-HRT N = 3080 | %  | P   |
|------------------|---------------|----|------------------|----|-----|
| Cirrhosis        |               |    |                  |    |     |     |
| No               | 3000          | 97.4%| 2988| 97.0%| 0.355|
| Yes              | 80            | 2.6% | 92  | 3.0% |
| HCC              |               |    |                  |    |     |     |
| No               | 3061          | 99.4%| 3043| 98.8%| 0.022|
| Yes              | 19            | 0.6% | 37  | 1.2% |
| Mortality (all-cause) | Survival | 3009| 97.7%| 2939| 95.4%| <0.001|
| Death            | 71            | 2.3% | 141 | 4.6% |

^aHRT, hormone replacement therapy.  
bHCC, hepatocellular carcinoma.

https://doi.org/10.1371/journal.pone.0271790.t002
HRT of <12, 12–36, and >36 months versus non-HRT were as follows: 1.04 (0.71–1.50), 0.69 (0.42–1.14), and 0.63 (0.38–1.04), respectively; 0.57 (0.28–1.19), 0.36 (0.13–0.99), and 0.54 (0.22–1.28), respectively; and 0.65 (0.41–0.83), 0.51 (0.31–0.73), and 0.25 (0.15–0.45), respectively. P was <0.042 for HCC with hormone use duration between 12 and 36 months. In all-cause mortality, P was 0.02 with hormone use duration <12 months, 0.004 with hormone use duration between 12 and 36 months, and <0.001 with hormone use duration >36 months (Table 3).

Discussion

In our 18-year follow-up, population-based PSM study, we discovered that HRT may lower the risk of HCC among postmenopausal women with chronic HBV infection; however, HRT had no significant effect on the risk of cirrhosis. Nonetheless, HRT was associated with significantly lower all-cause mortality in postmenopausal women with HBV.

Menopause is a process in which ovarian follicle loss [11] causes changes in hormone levels over time, eventually leading to menopausal transition [12, 13]. After that, it shifts to the postmenopausal period, in which the incidence of HBV-related HCC was reported to increase according to multiple epidemiological studies [14, 15].

In recent years, several reports regarding sex-dependent outcomes in chronic hepatitis B infection had been published. Baig stated an influence of estrogen in the protection and defense of hepatic cells against the development of chronic liver disease [16]. Wang et al. reported that the androgen pathway can increase the transcription of HBV through direct binding to the androgen-responsive element sites in viral enhancer I. This may explain a
higher HBV titer in male carriers and an increased risk of HCC [17]. Maria et al. identified an ER variant in postmenopausal women and men with HCC [18]. In addition, Almog et al. discovered that estrogen signals reduced the level of HBV mRNA in immunocompromised male mice that received transplants of HBV-transfected HepG-2 cells [19]. In agreement with these

![Survival curves of all-cause mortality in the HRT and non-HRT cohorts. HRT, hormone replacement therapy.](https://doi.org/10.1371/journal.pone.0271790.g003)

**Fig 3.** Survival curves of all-cause mortality in the HRT and non-HRT cohorts. HRT, hormone replacement therapy.

### Table 3. Adjusted hazard ratios for the risk of cirrhosis, all-cause mortality, and Hepatocellular Carcinoma (HCC) in the Hormone Replacement Therapy (HRT) cohort after Cox regression analysis.

| Variable                        | Cirrhosis | HCC | Mortality |
|---------------------------------|-----------|-----|-----------|
|                                 | HR(95%CI) | P   | HR(95%CI) | P | HR(95%CI) | P |
| **Use of HRT**                  |           |     |           |   |           |   |
| Never                           | 1.00 (Referent) |  | 1.00 (Referent) |  | 1.00 (Referent) |  |
| Ever                            | 0.82(0.60–1.10) | 0.166 | 0.50(0.29–0.87) | 0.014 | 0.49(0.37–0.65) | <0.001 |
| **Natural menopausal status**   |           |     |           |   |           |   |
| Premenopausal                   | 1.04(0.96–1.13) | 0.344 | 1.36(1.2–1.54) | <0.001 | 1.26(1.18–1.34) | <0.001 |
| Postmenopausal                  | 0.81(0.57–1.14) | 0.224 | 0.5(0.27–0.92) | 0.025 | 0.41(0.29–0.57) | <0.001 |
| **duration of HRT (months)**    |           |     |           |   |           |   |
| <12                             | 1.04(0.71–1.50) | 0.856 | 0.57(0.28–1.19) | 0.137 | 0.65(0.41–0.82) | 0.020 |
| 12–36                           | 0.69(0.42–1.14) | 0.148 | 0.36(0.13–0.99) | 0.042 | 0.51(0.31–0.73) | 0.004 |
| >36                             | 0.63(0.38–1.04) | 0.073 | 0.54(0.22–1.28) | 0.161 | 0.25(0.15–0.45) | <0.001 |

*aHRT, hormone replacement therapy.

*bHCC, hepatocellular carcinoma.

[https://doi.org/10.1371/journal.pone.0271790.t003](https://doi.org/10.1371/journal.pone.0271790.t003)
findings, Naugler et al. [19] demonstrated that estrogen signals suppressing Kupffer cell IL-6 production may play an essential role in protecting against the progression of HCC in women. Estrogen may play a pathogenetic role in reducing HCC risk due to its anti-inflammatory effects and the relationship of HCC with inflammation [20]. However, Kalaitzidis et al. [21] reported that estrogen may increase hepatocyte proliferation. Furthermore, studies of male HCC tumors and postmenopausal women have reported no protective anti-inflammatory effect induced by estrogen signals [22–24].

HBV-associated HCC has been reported to be higher in men and postmenopausal women than in other women [6–8]. A previous study revealed that sex hormones such as androgen and estrogen play different roles in the progression of HBV infection and in the development of HBV-related HCC [25]. Serum estrogen levels, which increase in pregnant women, were also reported to exert a protective effect against HCC [26]. The estrogen pathway protects against the progression of HBV infections and the development of HBV-associated HCC [27]. Wang et al. demonstrated that women with HBV have a lower risk of HCC when using oral contraceptives or HRT after menopause [28].

McGlynn et al. conducted a pooled analysis of data from 11 prospective US studies and revealed that oophorectomy significantly increased the risk of HCC [29]; the increased HCC risk with bilateral oophorectomy might be related not only to a decrease in estrogen levels but also to altered lipid levels [30]. Bilateral oophorectomy was also observed to increase hepatic androgen receptors in rodents [31]. On the basis of these findings, surgical menopause appears to be positively correlated with HCC development in women. Therefore, HRT might be beneficial to either surgically or naturally menopausal women with chronic HBV infection, who might be at risk of HCC after the cessation of menstruation.

More robust evidence is available regarding the role of HRT in suppressing HCC. Estrogen has been observed to exert protective effects against HCC development through interleukin 6 (IL-6) suppression, signal transducer and activator of transcription-3 (STAT3) inactivation, and tumor-associated macrophage inhibition [32–35]. Previous studies have also reported that HCC is an inflammation-related cancer [20, 36] and that IL-6-dependent STAT3 activation is a critical instigator of inflammation-induced liver cancer [36–39].

To control for confounding factors in our analyses, we measured and collected data on all known confounding factors, such as the identified comorbidities. We performed PSM to reduce or eliminate selection bias by balancing covariates between the HRT and non-HRT cohorts. Balancing covariates facilitates the task of matching participants with multiple characteristics. This strategy diminishes bias and improves the reliability of statistical inferences. Accordingly, our study was able to more precisely explore the role of HRT in postmenopausal HBV-infected women. Our results demonstrate that HRT during adulthood, regardless of the occurrence of menopause, may protect against the occurrence of HCC and reduce all-cause mortality. HRT significantly reduced the risk of HBV-associated HCC when HRT was used for 12–36 months in postmenopausal women; however, HRT use for >36 months and early hormone exposure did not protect against HCC. In premenopausal women, HRT exposure at an early age may influence the replication activity of HBV due to the early onset of menarche. This could then lead to hepatic lesions, chronic hepatitis, or mortality [40]. Our findings are consistent with those of Yu et al. [26], who demonstrated that the risk of HCC was lower among users of HRT than among nonusers and that the risk of HCC decreased linearly as the duration of HRT use increased. The strength of our study relative to that of Yu et al. is that we used PSM to control for biases; thus, the HRT and non-HRT groups were comparable with respect to the control variables. Moreover, we used a large-scale population-based study design, further increasing statistical power in investigating the association between HRT and the risk of HCC in postmenopausal women with chronic HBV infection. Although the
A 36-month group had a weaker response to HCC, we observed an association between HRT use and reduced HCC risk for treatment durations of between 1 and 3 years. The available data suggest improved survival regardless of the length of HRT treatment for postmenopausal women. A possible explanation for these observations is that multiple mechanisms underlie the effects of various synthetic estrogen treatments on hepatocarcinogenesis in some animal models [41, 42].

However, the study has limitations. First, we used a retrospective cohort design. Although we matched all identified confounding factors between the study cohorts, selection and observational bias still exists. However, because the NHIRD is a large and well-validated database, this bias was controlled sufficiently to demonstrate a clinically useful result. Second, although the NHIRD data used in our study were not the most recent available data, the analysis results obtained from this large-scale long-term cohort study are still convincing. Third, the NHIRD lacks specific laboratory information. Fourth, the ICD-9-CM codes could not be used to identify several comorbidities (e.g., fatty liver disease, nonalcoholic steatohepatitis, and nonalcoholic fatty liver disease). Fifth, the limitations of the NHIRD prevented clear identification of the causes of death; therefore, we could not compare the risks of HCC-related death in the patients with HBV. Nonetheless, these limitations do not affect the conclusions of this study. We thus recommend larger-scale prospective studies to further confirm the validity of our findings.

Conclusions
In conclusion, we identified a chemoprotective effect of HRT against HCC in postmenopausal women with chronic HBV infection who received HRT for at least 1 year but not more than 3 years. All-cause mortality was also lower after the initiation of HRT. Although HRT is an adjuvant therapy, its effectiveness should be validated before its recommendation for general use in postmenopausal women with chronic HBV.

Author Contributions
Conceptualization: Chun-Hsiang Wang.
Data curation: Ruey-Chang Lin, Yuan-Tsung Tseng.
Funding acquisition: Chun-Hsiang Wang, Ruey-Chang Lin.
Investigation: Ruey-Chang Lin.
Methodology: Yuan-Tsung Tseng.
Resources: Hua-Yin Hsu.
Software: Hua-Yin Hsu.
Supervision: Chun-Hsiang Wang.
Writing – review & editing: Chun-Hsiang Wang, Ruey-Chang Lin, Hua-Yin Hsu, Yuan-Tsung Tseng.

References
1. Hassan MM, Kaseb A, Li D, Patt AZ, Vauthey JN, Thomas MB, et al. Association between hypothyroidism and hepatocellular carcinoma: a case control study in the United States. Hepatology. 2009; 49 (5):1563–1570. https://doi.org/10.1002/hep.22793 PMID: 19399911
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004; 127(S Suppl 1):S27–S34. https://doi.org/10.1053/j.gastro.2004.09.013 PMID: 15508094
3. White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterol. 2017; 152(4):812–820. https://doi.org/10.1053/j.gastro.2016.11.020 PMID: 27889576

4. Firtminger HI, Reuber MD. Influence of adrenocortical, androgenic, and anabolic hormones on the development of carcinoma and cirrhosis of the liver in A x C rats fed N-2-fluorenylacetamide. J Natl Cancer Inst. 1961; 27:559–595. https://doi.org/10.1093/jnci/27.3.559 PMID: 13699763

5. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998; 4(9):1065–1067. https://doi.org/10.1038/2053 PMID: 9734402

6. Wang Y, Cheng J, Xu C, Liu S, Jiang S, Xu Q, et al. Quantitative methylation analysis reveals gender and age differences in p16INK4a hypermethylation in hepatitis B virus-related hepatocellular carcinoma. Liver Int. 2012; 32(3):420–428. https://doi.org/10.1016/j.lgi.2011.02.069.x PMID: 22192146

7. Zhu ZZ, Wang D, Cong WM, Jiang H, Yu Y, Wen BJ, et al. Sex-related differences in HBV DNA copy number alterations in hepatitis B virus-associated hepatocellular carcinoma. Asian Pac J Cancer Prev. 2012; 13(1):225–229. https://doi.org/10.7314/apjcp.2012.13.1.225 PMID: 22502674

8. Ruggieri A, Barbati C, Malorni W. Cellular and molecular mechanisms involved in hepatocellular carcinoma gender disparity. Int J Cancer. 2010; 127(3):499–504. https://doi.org/10.1002/ijc.25298 PMID: 20201099

9. Nagasue N, Ito A, Yokaya H, Ogawa Y, Ito A. Estrogen receptors in hepatocellular carcinoma. Cancer. 1986; 57(1):87–91. https://doi.org/10.1002/1097-0142(19860101)57:1<87::aid-cncr2820570118>3.0.co;2-3 PMID: 3005073

10. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, et al. Estrogen replacement reduces risk and increases survival times of women with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2017; 15(11):1791–1799. https://doi.org/10.1016/j.cgh.2017.05.036 PMID: 28579181

11. Nanette S. Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am. 2011; 38(3):455–466. https://doi.org/10.1016/j.ogc.2011.05.004 PMID: 21961713

12. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in midlife: implications for forecasting menopause. Hum Reprod. 1992; 7(10):1342–1346. https://doi.org/10.1093/oxfordjournals.humrep.a137570 PMID: 1291557

13. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab. 1987; 65(6):1231–1237. https://doi.org/10.1210/jcem-65-6-1231 PMID: 3119654

14. Meldrum DR, Tataryn IV, Frumar AM, Erlik Y, Lu KH, Judd HL. Gonadotropins, estrogen, and adrenal steroids during the menopausal hot flash. J Clin Endocrinol Metab. 1980; 50(4):685–689. https://doi.org/10.1210/jcem-50-4-685 PMID: 6444954

15. Quigley MM, Hammond CB. Estrogen-replacement therapy-help or hazard? N Engl J Med. 1979; 301(12):646–648. https://doi.org/10.1056/NEJM197909203011206 PMID: 471002

16. Baig S. Gender disparity in infections of hepatitis B virus. Journal of the College of Physicians and Surgeons—Pakistan. 2009; 19(9):598–600. [PubMed] [Google Scholar] PMID: 19728952

17. Wang S.-H., Yeh S.-H., Lin W.-H., Wang H.-Y., Chen D.-S., Chen P.-J. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology. 2009; 50(5):1392–1402. https://doi.org/10.1002/hep.23163 [PubMed] [CrossRef] [Google Scholar] PMID: 19670412

18. Maria N. D., Manno M., Villia E. Sex hormones and liver cancer. Molecular and Cellular Endocrinology. 2002; 193(1–2):59–63. https://doi.org/10.1016/s0303-7207(02)00096-5 [PubMed] [CrossRef] [Google Scholar] PMID: 12161002

19. Almog Y., Klein A., Adler R., Laub O., Tur-Kaspa R. Estrogen suppresses hepatitis B virus expression in male athymic mice transplanted with HBV transfected Hep G-2 cells. Antiviral Research. 1992; 19(4):285–293. https://doi.org/10.1016/0166-3542(92)90010-3 [PubMed] [CrossRef] [Google Scholar] PMID: 1483321

20. Beraisain C, Perugorria MJ, Latasa MU, Castillo J, Goni S, Santamaria M, et al: The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood). 2009, 234: 713–725. https://doi.org/10.3181/0901-MR-12 PMID: 19429859

21. Kalaitzidis D, Gilmore TD: Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab. 2005, 16: 46–52. https://doi.org/10.1016/j.tem.2005.01.004 PMID: 15734144

22. Jiang R., Deng L., Zhao L., et al: miR-22 promotes HBV-related hepatocellular carcinoma development in males. Clinical Cancer Research. 2011; 17(17):5593–5603. https://doi.org/10.1158/1078-0432.CCR-10-1734 [PubMed] [CrossRef] [Google Scholar] PMID: 21750200
32. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. International Journal of Cancer. 2009; 124(12):2766–2770. https://doi.org/10.1002/ijc.24281 [PubMed] [CrossRef] [Google Scholar] PMID: 19267406

33. Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T, et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer. 2009; 125(10):2264–2269. https://doi.org/10.1002/ijc.24720 PMID: 19585572

34. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009; 124(12):2766–2770. https://doi.org/10.1002/ijc.24281 PMID: 19267406

35. Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL, Wu JC, et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol. 2007; 33(3):208–212. https://doi.org/10.1016/j.ejso.2006.10.036 PMID: 17140760

36. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008; 267(2):204–215. https://doi.org/10.1016/j.canlet.2008.03.028 PMID: 18448242

37. Calvisi DF. Dr. Jekyll and Mr. Hyde: a paradoxical oncogenic and tumor suppressive role of signal transducer and activator of transcription 3 in liver cancer. Hepatology. 2011; 54(1):9–12. https://doi.org/10.1002/hep.24435 PMID: 21608001

38. He G, Karin M. NF-kappaB and STAT3—key players in liver inflammation and cancer. Cell Res. 2011; 21(1):159–168. https://doi.org/10.1038/cr.2010.183 PMID: 21187858

39. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006; 130(4):1117–11128. https://doi.org/10.1053/j.gastro.2006.01.006 PMID: 16618406

40. Medina K. L., Strasser A., & Kincade P. W. (2000). Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood, The Journal of the American Society of Hematology, 95(6), 2059–2067. PMID: 10706875

41. Mishkin SY, Farber E, Ho RK, Mulay S, Mishkin S. Evidence for the hormone dependency of hepatic hyperplastic nodules: inhibition of malignant transformation after exogenous 17α-estradiol and tamoxifen. Hepatology. 1983; 3(3):308–316. https://doi.org/10.1002/hep.1840030306 PMID: 6840677

42. Shimizu I, Yasuda M, Mizobuchi Y, Ma YR, Liu F, Shibah M, et al. Suppressive effect of estradiol on chemical hepatocarcinogenesis in rats. Gut. 1998; 42(1):112–119. https://doi.org/10.1136/gut.42.1.112 PMID: 9505896